Cinacalcet Actions in Familial Primary Hyperparathyroidism
This study will evaluate safety and efficacy of short- and long-term Cinacalcet in treatment
of hypercalcemia of familial primary hyperparathyroidism. The study population will include
patients with primary hyperparathyroidism caused by multiple endocrine neoplasia type 1 or
type 2A. This is a prospective unblinded pilot study, where each patient will serve as
his/her own control. It will include 6 one-week-long admissions, over a 1 year period.
Main measurements will be tests of hyperparathyroidism such as parathyroid hormone and serum
calcium as well as tests of nonparathyroid tumors. The latter tests may include hormones
released by the tumors and images of the tumors.
Interventional
Primary Purpose: Treatment
United States: Federal Government
060163
NCT00325104
May 2006
March 2007
Name | Location |
---|---|
National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda, Maryland 20892 |